Blood pressure variability and outcomes across antihypertensive regimens

Most conversations about blood pressure start and end with a single number. Your systolic hits 142 in the office, and the visit suddenly pivots toward whether you need a prescription. That number matters -- but it tells only part of the story. A growing body of evidence, including a 2025 analysis published in Hypertension, suggests that how much your blood pressure swings from reading to reading may be just as predictive of cardiovascular risk as where your average lands (https://pubmed.ncbi.nlm.nih.gov/42345116/). Different medications control that swing very differently. If your clinician has not brought up blood pressure variability yet, this post explains why it deserves a place in your next conversation.

What blood pressure variability actually means

Blood pressure is not a fixed number. It moves throughout the day -- lower during sleep, higher in the morning surge, reactive to stress, caffeine, a brisk walk, or a tense phone call. That is normal physiology. Blood pressure variability (BPV) becomes a clinical concern when the swings are larger than expected, more erratic than the usual daily pattern, or when they track alongside meaningful cardiovascular risk.

Clinicians measure BPV in a few ways. Visit-to-visit variability compares readings taken at separate clinic appointments over weeks or months. Day-to-day variability comes from home monitoring logs. And 24-hour ambulatory blood pressure monitoring (ABPM) -- a wearable cuff that records readings every 15 to 30 minutes around the clock -- gives the most complete picture by capturing nighttime dipping patterns that an office visit entirely misses (https://pubmed.ncbi.nlm.nih.gov/23612242/).

The nighttime pattern matters more than most people realize. Blood pressure normally dips 10 to 20 percent during sleep. People whose pressure does not dip -- called "non-dippers" -- have substantially higher rates of stroke, left ventricular hypertrophy, and kidney disease than people with the same average daytime pressure who do dip. A single afternoon office reading cannot tell you which category you are in.

A systematic review and meta-analysis in the Journal of Hypertension found that higher visit-to-visit variability was independently associated with increased risk of stroke, coronary heart disease, and all-cause mortality across populations already on treatment -- meaning the variability signal was not just a proxy for poorly controlled average pressure (https://pubmed.ncbi.nlm.nih.gov/26848994/). The conclusion that variability is its own risk factor, not just a marker of chaotic control, has held up across multiple subsequent analyses.

Why your medication choice shapes the swing

Not all antihypertensive medications reduce BPV equally, and the differences are not subtle. A landmark analysis by Rothwell and colleagues in Lancet Neurology examined data from multiple trials and found that beta-blockers -- particularly atenolol -- were associated with significantly higher visit-to-visit variability in systolic blood pressure compared with calcium channel blockers (CCBs), and that higher variability on beta-blockers translated into worse stroke outcomes (https://pubmed.ncbi.nlm.nih.gov/20206534/). This finding helped shift thinking about beta-blockers as a first-line hypertension agent for patients without compelling indications like heart failure or recent myocardial infarction.

A related meta-analysis published in The Lancet looked at the class-level effects on interindividual variability and confirmed that long-acting CCBs -- amlodipine being the most studied -- consistently produced the lowest variability among major drug classes, followed by ACE inhibitors and angiotensin receptor blockers (ARBs) (https://pubmed.ncbi.nlm.nih.gov/20167349/). Thiazide diuretics occupied a middle range. Beta-blockers, particularly shorter-acting formulations, came out worst for variability regardless of how well they lowered the average number.

This does not mean beta-blockers are wrong for you. If you have heart failure with reduced ejection fraction, a recent heart attack, or an arrhythmia requiring rate control, the evidence for beta-blockers in those settings is strong and they remain appropriate. What the variability data tells us is that choosing a beta-blocker purely to lower blood pressure -- without one of those compelling indications -- may come with a cost that the average reading does not capture.

Hydrochlorothiazide (HCTZ), one of the most commonly prescribed blood pressure medications in the country, deserves a specific note. A meta-analysis in the Journal of the American College of Cardiology found that HCTZ was less effective at lowering 24-hour blood pressure load compared with other agents despite similar office readings -- a finding that speaks directly to variability, because what happens during the full 24-hour cycle matters far more than a brief office snapshot (https://pubmed.ncbi.nlm.nih.gov/21251579/).

How a real evaluation should work

The 2017 ACC/AHA hypertension guidelines define high blood pressure as 130/80 mmHg or above and recommend confirming the diagnosis with out-of-office measurements before starting treatment in most cases (https://pubmed.ncbi.nlm.nih.gov/29133354/). That recommendation exists precisely because white-coat hypertension -- elevated readings in the clinic that normalize at home -- is common enough to change management in a meaningful percentage of people.

At NoMi Beach Health, we take that recommendation seriously. When blood pressure is the question, what clinicians look for includes the pattern across multiple readings rather than a single office number, a 24-hour ambulatory study or a two-week home log for anyone where the office picture is unclear, and a medication review for anyone already on treatment whose readings seem volatile rather than simply elevated.

We also ask about sleep. Obstructive sleep apnea is one of the most consistent drivers of non-dipping patterns and of treatment-resistant hypertension. If you are waking unrefreshed, snoring, or tired despite adequate sleep time, that conversation happens before -- or alongside -- any prescription decision. We look at sodium intake, alcohol use, NSAID use (ibuprofen and naproxen both raise blood pressure and blunt medication response), and any hormonal factors that might be widening the variability. If this last piece is relevant to you, our post on perimenopause symptoms and HRT covers how hormonal shifts alter vascular tone in ways that directly affect blood pressure management.

Sex differences and the variability gap

Women -- particularly those moving through perimenopause and menopause -- experience blood pressure variability differently than men of the same age. Declining estrogen reduces baroreflex sensitivity (the body's ability to smooth out pressure spikes), increases sympathetic nervous system tone, and alters arterial stiffness in ways that widen the variability window (https://pubmed.ncbi.nlm.nih.gov/35022524/). The clinical implication is that a woman in her late 40s whose blood pressure has recently become harder to read -- sometimes normal, sometimes elevated, sometimes alarmingly high during a hot flash -- is not simply non-compliant or anxious. She may have a physiology-driven BPV problem that requires a different therapeutic lens.

This does not automatically mean hormone therapy fixes blood pressure. The relationship is more nuanced. But it does mean that a hypertension workup in a perimenopausal woman is incomplete if it does not account for the hormonal context. We address this routinely in our concierge primary care model, where visits are long enough to connect those dots.

Choosing a regimen with variability in mind

If you are currently taking a beta-blocker for blood pressure alone -- not for heart failure, arrhythmia, or post-cardiac event protection -- and your readings are variable rather than consistently elevated, it is worth asking whether the regimen is working the way it should. The European Society of Hypertension position on ABPM notes that ambulatory monitoring is the most reliable way to identify inadequate control and nocturnal patterns that office visits miss (https://pubmed.ncbi.nlm.nih.gov/23612242/).

A long-acting CCB like amlodipine, or an ARB like losartan or olmesartan, may produce steadier 24-hour control with lower variability for patients without the specific indications that favor beta-blockers. Combination therapy -- such as an ACE inhibitor or ARB paired with a CCB -- is frequently more effective at stabilizing pressure around the clock than either agent alone, and is increasingly a first-line choice for patients who need meaningful reduction rather than modest single-agent control.

For a broader look at where hypertension treatment currently stands, including first-line options, dosing strategies, and when secondary causes need to be ruled out, see our detailed guide on hypertension treatment options 2026. And if you want to understand how concierge primary care changes the quality of this workup -- more time, same clinician every visit, labs reviewed before you walk in the door -- our concierge primary care guide explains the model in full.

The short version is this: blood pressure management in 2025 is not about getting one number under a threshold. It is about what your pressure does over 24 hours, what drives the swings, and whether your medication is actually smoothing them or just nudging the average down on clinic days. Those are different problems with different solutions.

What we look at before recommending any change

Visit-to-visit variability data, reviewed across your chart history. A 24-hour ambulatory study if the office picture is inconsistent. A medication review covering every agent that affects blood pressure -- prescription and over-the-counter. A sleep history. A full metabolic panel including kidney function, because variability damages target organs and we want to know baseline status. And a conversation about your goals: what you are willing to take, how many pills matter to you, and what trade-offs you are prepared to make.

That conversation takes time. It does not fit into a 12-minute appointment. It is the kind of primary care we built NoMi Beach Health to deliver.

If your blood pressure readings feel unpredictable, if you have been on the same regimen for years without anyone re-evaluating the variability picture, or if you just want a clinician who will actually look at the full 24-hour story rather than one office number -- we are here for that conversation.

Book a primary care visit at NoMi Beach Health or call us at (786) 744-5152. Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) will review your history, order the right monitoring, and give you a real answer about whether your current regimen is working as well as it should.